Glimepiride Eg (Glimepiride)

Glimepiride Eg is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and weight management alone are insufficient to achieve target glycemic control.

• Improves fasting and post‑prandial blood glucose levels.
• Can be used as monotherapy or in combination with other oral antidiabetic agents.
• May be considered when patients require a sulfonylurea with a long duration of action.
• Helps reduce HbA1c when taken consistently as prescribed.
• Intended for adult patients with adequate pancreatic beta‑cell function.

Glimepiride Eg may cause a range of adverse effects, some of which are frequent and mild, while others are less common but potentially serious.

Common

• Low blood sugar (hypoglycemia), especially if meals are missed.
• Nausea or mild gastrointestinal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as rash, itching, or swelling of the face and throat.
• Blood disorders including leukopenia or thrombocytopenia.

Before starting Glimepiride Eg, certain health conditions and patient factors should be evaluated to minimize risks.

• Assess renal and hepatic function; dose adjustments may be needed in impairment.
• Use cautiously in elderly patients due to increased hypoglycemia risk.
• Not recommended during pregnancy or breastfeeding because safety data are limited.
• Monitor blood glucose regularly to detect hypoglycemia early.
• Avoid alcohol consumption, which can potentiate hypoglycemic episodes.
• Review concomitant medications that affect insulin secretion or glucose metabolism.
• Ensure patients have adequate pancreatic beta‑cell reserve before initiating therapy.

Glimepiride Eg can interact with several drugs, altering its glucose‑lowering effect or increasing the risk of adverse reactions.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride plasma levels.
• MAO‑B inhibitors (e.g., selegiline) that can enhance hypoglycemic risk.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can increase blood glucose levels.
• Corticosteroids or atypical antipsychotics, which may reduce glimepiride effectiveness.